Fig. 1.

SELENOM is downregulated in livers from HFD-treated mice and related to the development of NAFLD. A The mRNA and protein level of SELENOM in AML12 hepatocytes treated with PA (75 μM) (n = 6; *P < 0.05). B The mRNA and protein level of SELENOM in vitro were detected in Veh, SELENOM, PA and SELENOM + PA (n = 3; *P < 0.05). C Bodyweight of Chow- and HFD-treated mice (n = 6; *P < 0.05). D The mRNA and protein level of SELENOM in livers from Chow- and HFD-treated mice (18 W) (n = 6; *P < 0.05). E The mRNA and protein level of SELENOM was measured in livers from WT, SELENOM^−/−, HFD, SELENOM^−/− + HFD (n = 6; *P < 0.05). F Bodyweight in mice of WT, SELENOM^−/−, HFD and SELENOM^−/− + HFD (n = 6; *P < 0.05). G–K Blood glucose levels, ALT, AST, triglyceride, total cholesterol in the blood serum isolated from WT, SELENOM^−/−, HFD and SELENOM^−/− + HFD mice (n = 6; *P < 0.05). Values represent means ± SEM